EGFR and non-small cell lung carcinoma: Human non-small cell lung cancer (NSCLC), with activating mutations in epidermal growth factor receptor (EGFR), responds very well to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib; however, these responses are reduced by acquired resistance [32].